Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05188508
Title Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

high grade glioma

low grade glioma

Therapies

Olaparib + Pembrolizumab + Temozolomide

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST